Translational Development Acquisition Corp.

Translational Development Acquisition Corp., trading under the warrant ticker TDACW, is a blank-check company focused on the life sciences and biotechnology sector, with a name that signals an intent to target companies engaged in translating scientific research into clinical or commercial applications. The SPAC filed a Form 425 on May 27, 2026, indicating active communications related to a prospective business combination. Form 425 filings are required by the SEC during ongoing merger or acquisition discussions and reflect a deal process that is in motion. Full details on the sponsor, IPO vintage, and transaction timeline are tracked on SpacDesk — sign up at SpacDesk for comprehensive SPAC deal data and real-time filing alerts.